Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Indivior PLC (INDV : NSDQ)

• Company Description    Indivior PLC operates as a specialty pharmaceutical company. It is engaged in discovering and developing medications and treatment for alcohol addiction, opioid overdose, cocaine intoxication and co-occurring conditions, such as schizophrenia. The Company markets and promotes SUBOXONE (buprenorphine and naloxone) Sublingual Film, SUBOXONE (buprenorphine and naloxone) Sublingual Tablet, and SUBUTEX (buprenorphine) Sublingual Tablet, each buprenorphine-based treatment for opioid. Indivior PLC is based in United States. Number of Employees: 1,051

• Price / Volume Information    Yesterday's Closing Price: $31.34 Daily Weekly Monthly 20 Day Moving Average: 2,389,351 shares Shares Outstanding: (millions) Market Capitalization: $ (millions) Beta: 0.68 52 Week High: $32.42 52 Week Low: $7.62 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 31.79% 28.34% 12 Week 33.59% 28.05% Year To Date 152.13% 120.39%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 10710 Midlothian Turnpike Suite 125 - North Chesterfield,VA 23235 USA ph: 804-379-1040 fax: 804-379-1215 investorrelations@indivior.com http://www.indivior.com

• General Corporate Information    Officers Mark Crossley - Chief Executive Officer David Wheadon - Chairman Ryan Preblick - Chief Financial Officer Woodrow Anderson - Senior Vice President Juliet Thompson - Director Peer Information Indivior PLC (GSAC) Indivior PLC (CASI) Indivior PLC (ALCD.) Indivior PLC (OMNN) Indivior PLC (CGPI.) Indivior PLC (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: G4766E116 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 02/19/26 Share - Related Items Shares Outstanding: Most Recent Split Date: (:1) Beta: 0.68 Market Capitalization: $ (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $0.65 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $2.16 Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: 0.00 Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 02/19/26

• Fundamental Ratios P/E Current FY Estimate: 14.49 Trailing 12 Months: 15.99 PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: 17.22 Price / Sales: - EPS Growth vs. Year Ago Period: 33.33% vs. Previous Quarter: 41.18% Sales Growth vs. Year Ago Period: 2.28% vs. Previous Quarter: 3.97% ROE 09/30/25 - -90.79 06/30/25 - -86.28 03/31/25 - -97.29 ROA 09/30/25 - 17.91 06/30/25 - 16.26 03/31/25 - 15.74 Current Ratio 09/30/25 - 0.96 06/30/25 - 0.90 03/31/25 - 0.88 Quick Ratio 09/30/25 - 0.79 06/30/25 - 0.76 03/31/25 - 0.72 Operating Margin 09/30/25 - 21.10 06/30/25 - 19.44 03/31/25 - 19.15 Net Margin 09/30/25 - 9.83 06/30/25 - 6.65 03/31/25 - -4.02 Pre-Tax Margin 09/30/25 - 16.10 06/30/25 - 15.60 03/31/25 - 0.00 Book Value 09/30/25 - - 06/30/25 - - 03/31/25 - -2.07 Inventory Turnover 09/30/25 - 1.41 06/30/25 - 1.26 03/31/25 - 1.37 Debt-to-Equity 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Capital 09/30/25 - - 06/30/25 - - 03/31/25 - -

Powered by Zacks Investment Research ©